All In Biotech

Drug Trial Radar · NCT02782741

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe Disease

Last checked: Nov 20, 2026Latest source record: Apr 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Nov 2, 2016

Primary completion

Mar 19, 2020

Study completion May 31, 2023

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
May 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To determine the effect of avalglucosidase alfa treatment on respiratory muscle strength measured by percent (%) predicted forced vital capacity (FVC) in the upright position, as compared to alglucosidase alfa. Secondary Objective: To determine the safety and effect of avalglucosidase alfa treatment on functional endurance (6-minute walk test, inspiratory muscle strength (maximum inspiratory pressure), expiratory muscle strength (maximum expiratory pressure), lower extremity muscle strength (hand-held dynamometry), motor function (Quick Motor Function Test), and health-related quality of life (Short Form-12).

Conditions

  • Glycogen Storage Disease Type II;Pompe's Disease

Interventions

  • Avalglucosidase alfa (GZ402666)Drug

    Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous

  • Alglucosidase alfa (GZ419829)Drug

    Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PAP: Change From Baseline in Percent Predicted FVC in Upright Position at Week 49Time frame: Baseline, Week 49

Locations

69 sites in 25 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8400015

    Phoenix, Arizona

  • Investigational Site Number 8400020

    Los Angeles, California

  • Investigational Site Number 8400011

    Orange, California

  • Investigational Site Number 8400017

    Stanford, California

  • Investigational Site Number 8400016

    Gainesville, Florida

  • Investigational Site Number 8400007

    Decatur, Georgia

  • Investigational Site Number 8400023

    Chicago, Illinois

  • Investigational Site Number 8400002

    Iowa City, Iowa

  • Investigational Site Number 8400012

    Kansas City, Kansas

  • Investigational Site Number 8400010

    Boston, Massachusetts

  • Investigational Site Number 8400001

    Detroit, Michigan

  • Investigational Site Number 8400019

    Minneapolis, Minnesota

  • Investigational Site Number 8400026

    Great Neck, New York

  • Investigational Site Number 8400008

    Valhalla, New York

  • Investigational Site Number 8400006

    Durham, North Carolina

  • Investigational Site Number 8400009

    Cincinnati, Ohio

  • Investigational Site Number 8400014

    Portland, Oregon

  • Investigational Site Number 8400025

    Pittsburgh, Pennsylvania

  • Investigational Site Number 8400018

    Salt Lake City, Utah

  • Investigational Site Number 8400005

    Fairfax, Virginia

  • Investigational Site Number 8400024

    Morgantown, West Virginia

  • Investigational Site Number 0320001

    Caba, Argentina

  • Investigational Site Number 0360001

    Auchenflower, Australia

  • Investigational Site Number 0400001

    Vienna, Austria

  • Investigational Site Number 0560003

    Brussels, Belgium

  • Investigational Site Number 0560001

    Leuven, Belgium

  • Investigational Site Number 0760004

    Brasília, Brazil

  • Investigational Site Number 0760001

    São Paulo, Brazil

  • Investigational Site Number 1240003

    Hamilton, Canada

  • Investigational Site Number 1240002

    Montreal, Canada

  • Investigational Site Number 2030001

    Prague, Czechia

  • Investigational Site Number 2080003

    København Ø, Denmark

  • Investigational Site Number 2500008

    Angers, France

  • Investigational Site Number 2500007

    Bordeaux, France

  • Investigational Site Number 2500011

    Brest, France

  • Investigational Site Number 2500004

    Bron, France

  • Investigational Site Number 2500010

    Clermont-Ferrand, France

  • Investigational Site Number 2500005

    Lille, France

  • Investigational Site Number 2500006

    Marseille, France

  • Investigational Site Number 2500001

    Paris, France

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.